Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 258

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Circulating Biomarkers of Distinct Pathophysiological Pathways in Heart Failure with Preserved vs. Reduced Left Ventricular Ejection Fraction

Open access
Sanders-van Wijk, S., van Empel, V., Davarzani, N., Maeder, M. T., Handschin, R., Pfisterer, M. E., Brunner-La Rocca, H. P., for the TIME-CHF investigators · 2015 · European Journal of Heart Failure

Abstract

Aims: The aim of this study was to evaluate whether biomarkers reflecting pathophysiological pathways are different between heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF) and whether the prognostic value of biomarkers is different in HFpEF vs. HFrEF. Methods and results: A total of 458 HFrEF (LVEF ≤40%) and 112 HFpEF (LVEF ≥50%) patients aged ≥60 years with NYHA class ≥II from TIME-CHF were included. Endpoints are 18-month overall and HF hospitalization-free survival. After correction for baseline characteristics that differed between the HF types, i.e. age, gender, body mass index, systolic blood pressure, cause of HF, and AF, HFpEF patients exhibited higher soluble interleukin 1 receptor-like 1 [ST2; 37.6 (28.5–54.7) vs. 35.7 (25.6–52.2), P = 0.02], high sensitivity C-reactive protein (hsCRP; 8.54 (3.39–25.86) vs. 6.66 (2.42–15.39), P = 0.01), and cystatin-C [1.94 (1.57–2.37) vs. 1.75 (1.39–2.12), P = 0.01]. In contrast, HFrEF patients exhibited higher NT-proBNP [2142 (1473–4294) vs. 4202 (2239–7411), P < 0.001], high sensitivity troponin T [hsTnT; 27.7 (16.8–48.0) vs. 32.4 (19.2–59.0), P = 0.03], and haemoglobin [124 (110–135) vs. 134 (122–145), P < 0.001]. In addition to these clinical characteristics, NT-proBNP, haemoglobin, cystatin-C, hsTnT, and ST2 improved the area under the curve from 0.86 (0.82–0.89) to 0.91 (0.87–0.94; P < 0.001) for discriminating HFpEF from HFrEF. There were no significant interactions between HFpEF and HFrEF when considering the prognostic value of the investigated biomarkers (P > 0.10 for both endpoints), except for cystatin-C which had less prognostic impact in HFpEF (P < 0.01). Conclusion: Biomarker levels suggest a different amount of activation of several pathophysiological pathways between HFpEF and HFrEF. No important differences in the prognostic value of biomarkers in HFpEF vs. HFrEF were found except for cystatin-C, and for NT-proBNP in the NT-proBNP-guided study arm only, both of which had less prognostic value in HFpEF. Trial registration: ISRCTN43596477

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.414

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 258

Metadata

Authors
Sanders-van Wijk, S., van Empel, V., Davarzani, N., Maeder, M. T., Handschin, R., Pfisterer, M. E., Brunner-La Rocca, H. P., & for the TIME-CHF investigators
Venue
European Journal of Heart Failure
Published
2015-10-01
Volume
17
Issue
10
Pages
1006-1014
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W1900173585
Cited by
258
References
40
FWCI
16.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating Biomarkers of Distinct Pathophysiological Pathways in Heart Failure with Preserved vs. Reduced Left Ventricular Ejection Fraction. https://app.cochat.ai/papers/10.1002/ejhf.414
The paper
Sanders-van Wijk, S., van Empel, V., Davarzani, N., Maeder, M. T., Handschin, R., Pfisterer, M. E., Brunner-La Rocca, H. P., & for the TIME-CHF investigators. (2015). Circulating Biomarkers of Distinct Pathophysiological Pathways in Heart Failure with Preserved vs. Reduced Left Ventricular Ejection Fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.